Latest News and Press Releases

PITTSBURGH, May 16, 2025 (GLOBE NEWSWIRE) -- BlueSphere Bio, a clinical stage drug development company focused on novel T cell based therapies, today announced the appointment of Alan Korman, Ph.D.,...

PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- BlueSphere Bio, a drug development company focused on the discovery of novel T-cell receptor (TCR) based therapies, announced it has been accepted as a...

Through this partnership, BlueSphere will treat patients with acute myeloid and lymphocytic leukemia, and myeloid dysplastic syndrome, who have active disease or are at high risk for relapse, with the...

PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for...

TCX-101 Clinical Program: TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse  ...

PITTSBURGH, May 30, 2024 (GLOBE NEWSWIRE) -- BlueSphere Bio, a drug development company focused on the discovery of novel T-cell receptor (TCR)-based therapies with a robust clinical pipeline and...

PITTSBURGH, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...

PITTSBURGH, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...

Dr. Bahceci brings more than two decades of combined clinical and drug development experience PITTSBURGH, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell...

BSB-1001 is the first product candidate from the TCX-101 platformData supports BSB-1001 as a potential treatment to improve outcomes for patients with acute myeloid leukemia (AML) receiving a...